Veterinary pharmaceutical manufacturer with global distribution and regulatory focus
Dechra manufactures and distributes veterinary pharmaceuticals across 63 countries, operating a sales-driven organization (17 active sales roles) paired with heavy manufacturing and R&D capacity (12 manufacturing, 7 research hires). The tech stack reflects a regulated-industry posture: Veeva Vault and Benchling for compliance and lab workflows, Oracle/Hyperion for finance, Salesforce for sales ops. Active projects center on forecasting, monoclonal antibody studies, and continuous improvement — suggesting simultaneous scaling of commercial operations and product development while managing production efficiency challenges.
Notable leadership hires: Continuous Improvement Lead, Marketing Category Lead, Packing Line Lead
Dechra is a publicly listed veterinary pharmaceutical company headquartered in Northwich, Cheshire, founded in 1997. The business develops, manufactures, and distributes high-quality veterinary drugs and related products exclusively through veterinary channels. Operations span 26 countries with direct sales and marketing presence, plus distribution into 63 additional countries via partner networks. The company's stated focus is sustainable improvement of animal health and welfare through evidence-based treatments, training, and support for veterinary professionals. Manufacturing and supply-chain efficiency are central operational priorities, as is portfolio expansion through both internal product development (PK/PD studies, immunogenicity assessment) and external IP acquisition.
Dechra recruits across 11 countries: United Kingdom, United States, Mexico, Netherlands, Spain, Croatia, Germany, Bulgaria, Belgium, Canada, and France.
Dechra uses Veeva Vault and Benchling for regulatory/lab compliance, Salesforce and Oracle for commercial and financial operations, Microsoft Office tools, and GCP for cloud infrastructure. HPLC instruments support manufacturing analytics.
Other companies in the same industry, closest in size